Global sleep and breathing health company ResMed has finalized its acquisition of Noctrix Health in a deal valued at up to $340 million, marking a notable expansion of its product and therapy offerings in the sleep health space. The transaction, which closed recently, brings Noctrix Health’s tonic motor activation (TOMAC) therapy platform under the ResMed umbrella, targeting patients who suffer from restless legs syndrome (RLS) a condition that significantly disrupts sleep quality for millions of people worldwide.
Noctrix Health had developed a wearable neurostimulation device designed to treat moderate-to-severe restless legs syndrome through its proprietary TOMAC therapy, which works by delivering targeted electrical stimulation to the legs. The therapy represents a non-pharmacological treatment pathway for RLS, an area where treatment options have historically been limited and where patients often face challenges with long-term medication adherence or side effects. The acquisition of Noctrix Health is structured as an upfront payment combined with additional milestone-based consideration, with the total deal reaching up to $340 million depending on the achievement of certain commercial and regulatory milestones.
ResMed’s Chief Executive Officer Mick Farrell highlighted the strategic importance of the transaction, describing Noctrix Health’s TOMAC therapy as a meaningful addition to the company’s growing portfolio of sleep health solutions. ResMed, which is widely known for its continuous positive airway pressure (CPAP) devices and software solutions for sleep apnea management, has been actively broadening its reach across various sleep-related conditions. The inclusion of an RLS-focused therapy aligns directly with that broader strategic direction, allowing the company to address a wider spectrum of sleep disorders beyond its core sleep apnea business.
Restless legs syndrome affects a significant portion of the global population and is frequently underdiagnosed and undertreated. The condition causes uncomfortable sensations in the legs, typically worsening at night, and leads to severe disruptions in sleep. By integrating Noctrix Health’s technology and clinical expertise through the acquisition of Noctrix Health, ResMed positions itself to serve patients who have not yet found effective relief through existing treatment options. The combined organization is expected to continue development efforts and pursue broader commercialization of the TOMAC platform as part of ResMed’s long-term growth strategy in sleep health.
